Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-12-29
- Last Posted Date
- 2016-07-25
- Lead Sponsor
- Nasser Hanna, M.D.
- Target Recruit Count
- 8
- Registration Number
- NCT00417248
- Locations
- 🇺🇸
Medical & Surgical Specialists, LLC, Galesburg, Illinois, United States
🇺🇸Indiana University Cancer Center, Indianapolis, Indiana, United States
🇺🇸Fort Wayne Oncology & Hematology, Inc, Fort Wayne, Indiana, United States
Sorafenib to Overcome Resistance to Systemic Chemotherapy in Androgen-independent Prostate Cancer
- First Posted Date
- 2006-12-21
- Last Posted Date
- 2014-04-07
- Lead Sponsor
- Oncology Specialists, S.C.
- Target Recruit Count
- 22
- Registration Number
- NCT00414388
- Locations
- 🇺🇸
Onocology Specialists, S.C, Niles, Illinois, United States
🇺🇸Oncology Specialists, S.C, Park Ridge, Illinois, United States
BATTLE Program: Sorafenib in Patients With NSCLC
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2016-02-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 105
- Registration Number
- NCT00411671
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Phase I Study of Perifosine + Sorafenib for Patients With Advanced Cancers
- First Posted Date
- 2006-11-14
- Last Posted Date
- 2014-02-19
- Lead Sponsor
- AEterna Zentaris
- Target Recruit Count
- 30
- Registration Number
- NCT00398814
Dosing and Effectiveness Study of Sorafenib and RAD001 in the Treatment of Patients With Advanced Kidney Cancer
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2022-06-06
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 78
- Registration Number
- NCT00392821
- Locations
- 🇺🇸
Norton Cancer Institute, Louisville, Kentucky, United States
🇺🇸Baptist Hospital East, Louisville, Kentucky, United States
🇺🇸Wellstar Cancer Research, Marietta, Georgia, United States
Paclitaxel and Carboplatin With Or Without Sorafenib In The First-Line Treatment Of Patients With Ovarian Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-10-20
- Last Posted Date
- 2014-12-22
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 85
- Registration Number
- NCT00390611
- Locations
- 🇺🇸
Northeast Arkansas Clinic, Jonesboro, Arkansas, United States
🇺🇸Florida Cancer Specialists, Fort Myers, Florida, United States
🇺🇸Holy Cross Hospital, Ft. Lauderdale, Florida, United States
Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML
- First Posted Date
- 2006-09-08
- Last Posted Date
- 2009-08-19
- Lead Sponsor
- University Hospital Muenster
- Target Recruit Count
- 200
- Registration Number
- NCT00373373
- Locations
- 🇩🇪
Klinikum der Universität zu Köln, Klinik I für Innere Medizin, Köln, Germany
🇩🇪Universitätsklinikum Münster, Medizinische Klinik A, Münster, Germany
🇩🇪Robert-Bosch Krankenhaus Stuttgart, Stuttgart, Germany
S0505 Sorafenib in Treating Patients With Advanced Soft Tissue Sarcomas
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2014-05-15
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 51
- Registration Number
- NCT00217620
- Locations
- 🇺🇸
Alta Bates Comprehensive Cancer Center, Berkeley, California, United States
🇺🇸West Michigan Cancer Center, Kalamazoo, Michigan, United States
🇺🇸Bronson Methodist Hospital, Kalamazoo, Michigan, United States
Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer
- First Posted Date
- 2003-07-09
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Eastern Cooperative Oncology Group
- Target Recruit Count
- 342
- Registration Number
- NCT00064350
- Locations
- 🇺🇸
Marshfield Clinic - Marshfield Center, Marshfield, Wisconsin, United States
🇺🇸Memorial Hospital, Carthage, Illinois, United States
🇺🇸St. Mary - Corwin Regional Medical Center, Pueblo, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.